A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto …
G Barilà, FM Quaglia, A Furlan, N Pescosta… - Annals of …, 2024 - Springer
Abstract Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still
represents an unmet clinical need. In the last years, daratumumab-bortezomib …
represents an unmet clinical need. In the last years, daratumumab-bortezomib …
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: final results of the phase 2 …
E Terpos, I Ntanasis‐Stathopoulos… - American Journal of …, 2024 - Wiley Online Library
The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple
myeloma (MM) has increased the number of those who become refractory to lenalidomide at …
myeloma (MM) has increased the number of those who become refractory to lenalidomide at …
Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM …
A Chari, J Martinez-Lopez, MV Mateos, J Blade… - 2018 - ascopubs.org
8002 Background: Len-refractory pts have poor outcomes, highlighting an unmet medical
need. In the phase 1b MMY1001 study (NCT01998971), D-Kd induced deep responses and …
need. In the phase 1b MMY1001 study (NCT01998971), D-Kd induced deep responses and …
[HTML][HTML] Efficacy of daratumumab in combination with standard of care regimens in lenalidomide-exposed or-refractory patients with relapsed/refractory multiple …
Introduction: The use of lenalidomide (len) in the treatment of newly diagnosed multiple
myeloma (NDMM) as induction and/or maintenance therapy is increasing. The majority of …
myeloma (NDMM) as induction and/or maintenance therapy is increasing. The majority of …
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
MA Moustafa, R Parrondo, MF Abdulazeez… - Anti-cancer …, 2024 - journals.lww.com
Daratumumab is an anti-CD38 mAb, used frequently in combination with lenalidomide and
pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone …
pomalidomide. No studies compared daratumumab plus lenalidomide and dexamethasone …
Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis
D Fric, M Stork, I Boichuk, V Sandecka… - European Journal of …, 2024 - Wiley Online Library
We performed retrospective analysis of relapsed/refractory multiple myeloma (RRMM)
patients previously exposed to daratumumab treated with ixazomib, lenalidomide …
patients previously exposed to daratumumab treated with ixazomib, lenalidomide …
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
A Chari, J Martinez-Lopez, MV Mateos… - Blood, The Journal …, 2019 - ashpublications.org
Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the …
G Mele, N Di Renzo, N Cascavilla… - Leukemia & …, 2023 - Taylor & Francis
Giuseppe Mele a, Nicola di renzo b, Nicola Cascavilla c, Angelo Michele Carella c, Attilio
Guarini d, Patrizio Mazza e, Lorella Melillo f, Vincenzo Pavone g, Giuseppe tarantini h …
Guarini d, Patrizio Mazza e, Lorella Melillo f, Vincenzo Pavone g, Giuseppe tarantini h …
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients–real world evidence analysis
M Stork, I Spicka, J Radocha, J Minarik, T Jelinek… - Annals of …, 2023 - Springer
We performed real world evidence (RWE) analysis of daratumumab, lenalidomide and
dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in …
dexamethasone (Dara-Rd) versus lenalidomide and dexamethasone (Rd) treatment in …
[HTML][HTML] P04: Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with previously treated multiple myeloma …
P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka… - …, 2022 - journals.lww.com
Methods: Pts with RRMM and≥ 1 prior line of therapy were randomized 1: 1 to receive D-Vd
or Vd. All pts received up to 8 (21-day) cycles of Vd (V 1.3 mg/m 2 SC on Days 1, 4, 8, and …
or Vd. All pts received up to 8 (21-day) cycles of Vd (V 1.3 mg/m 2 SC on Days 1, 4, 8, and …